Fairvalue-Calculator Fairvalue-Calculator
EN DE

STRAP (STRAP) Fair Value & Analysis

Healthcare · DK · Market cap 24.6M DKK

Pricekr 585.00
Fair Valuekr 358.34
Upside-38.7%
Quality95/100
Evidence: Low Range kr 236.50 – kr 447.92

Fair value as of: Jun 25, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

STRAP (STRAP) currently trades at kr 585.00, while our model-based Fair Value estimate is kr 358.34 — implying the stock looks roughly 38.7% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Strategic Partners A/S does not have significant operations. Previously, it was engaged in biotech activities. The company was formerly known as Orphazyme A/S and changed its name to Strategic Partners A/S in October 2024. Strategic Partners A/S was incorporated in 2009 and is based in Herlev, Denmark.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -84% Regeneron Pharmaceuticals, Inc (REGN) +109% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -64%

Frequently asked questions

Is STRAP (STRAP) undervalued?
As of Jun 25, 2026, our model estimates a fair value of kr 358.34 versus a price of kr 585.00 — about −39% (overvalued). Model-based estimate, not financial advice.
What is the fair value of STRAP?
Our 21-model fair value for STRAP is kr 358.34 (as of Jun 25, 2026), built from audited fundamentals. The current price is kr 585.00.
What is the quality score of STRAP?
STRAP has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.